# Utah Array BCI Platform **Type:** work **Status:** Draft **Confidence:** Medium **Focus:** brain-computer interfaces, neural engineering, intracortical electrodes, medical devices **Era:** 1990s-present; human research use since 2004 **Location:** University of Utah and Salt Lake City, UT **Updated:** 2026-06-18 **Pull:** *A Utah-originated electrode array became the standard recording tool for human brain-computer interface research.* ## Summary The Utah Array is a high-channel-count intracortical microelectrode array developed at the University of Utah and later commercialized through [Blackrock Neurotech](blackrock-neurotech.md). The platform records neural activity from the surface of the cortex at many simultaneous sites, which makes it possible to decode movement intent, test sensory feedback, and study long-duration human neural signals in research settings and, increasingly, in regulated medical-device paths. This page is about the research platform and its lineage, not only the company. The Utah claim is that a local invention became one of the most widely implanted intracortical BCI tools in the world and remains part of the most ambitious path from neural signal to useful action for people with paralysis and severe neurological disorders. ## Impact If implantable BCIs become practical medical products, the Utah Array lineage may be one of the field's foundational platforms. It has already supported research in cursor control, robotic-arm control, sensory restoration, speech decoding, and long-duration human neural recording across leading academic and clinical programs. The deeper impact is infrastructural: hundreds of labs globally use Utah Array hardware as a recording standard, which makes the design part of the substrate for an entire emerging field rather than a single company's product line. ## What Was Created The Utah Array packages many microelectrodes on a small grid that can be implanted on the cortical surface. Blackrock's commercial systems — including the Utah Array, NeuroPort, and related recording hardware — translate that platform into research-grade and medically regulated configurations. Public materials describe the Utah Electrode Array as the most-implanted and most-studied intracortical BCI electrode in history, with documented use across dozens of patients and more than 30,000 cumulative implantation days. Blackrock's MoveAgain system, which translates motor-cortex signals into device commands, has FDA Breakthrough Device designation. The next-generation Neuralace flexible-mesh design is the company's bet on higher channel counts and better chronic biocompatibility. ## Why It Mattered Brain-computer interfaces had existed as a research idea for decades, but human intracortical work needed a repeatable electrode platform that labs could trust, compare, and build on. The Utah Array gave the field a shared hardware layer. The open engineering problem remains chronic stability: implanted electrodes degrade as scar tissue forms and signal quality drops over months. Whether intracortical arrays win clinically — versus less invasive speech BCIs or different electrode architectures — is still unsettled. The Utah Array's importance is that it made the hardest human experiments possible at scale. ## Utah Context The platform was invented at the University of Utah by Richard Normann and commercialized through a 2008 university spinout that became Blackrock Neurotech. Salt Lake City now sits inside a small but globally outsized neuroengineering cluster that includes the university's neural engineering group, SCI Institute, Ripple Neuro, and Iris Biomedical. For Utah, the story is a long-horizon deep-tech bet: hardware-first, biology-aware, decades old, and at the substrate of an entire field rather than a fast consumer product cycle. ## People and Institutions - **Richard Normann** — University of Utah researcher credited with inventing the Utah Array. - **University of Utah neural engineering community** — the academic home where the array was developed and refined. - **[Blackrock Neurotech](blackrock-neurotech.md)** — Salt Lake City company that manufactures, commercializes, and advances the platform. - **Clinical and academic BCI research teams worldwide** — the labs and patient participants whose experiments established the platform's track record. ## Lessons for Builders - Platform standards can outlast any single product roadmap. A widely adopted research tool can become durable infrastructure even before a take-home medical device exists. - Medical timelines are measured in decades, not quarters. Breakthrough Device designation is not approval, and human-data track records matter more than launch rhetoric. - Geography can concentrate a field. Utah's neuroengineering cluster gives founders and engineers peer density that is hard to replicate elsewhere. - Chronic biocompatibility is the real product problem. Channel count and decoding algorithms matter, but scar tissue and signal decay decide whether an implant is useful outside a lab. ## Evidence - [Blackrock Neurotech](blackrock-neurotech.md) - [Source: Blackrock Neurotech and the Utah Array](blackrock-utah-array-medical-design.md) - [Blackrock Neurotech: Utah Array](https://blackrockneurotech.com/products/utah-array/) - [Blackrock Neurotech: NeuroPort Electrode](https://blackrockneurotech.com/products/neuroport-array/) - [MoveAgain FDA Breakthrough Device designation](https://blackrockneurotech.com/insights/blackrock-neurotechs-moveagain-brain-computer-interface-system-receives-breakthrough-device-designation-from-the-fda/) ## Open Questions - Which peer-reviewed clinical outcomes best support claims about long-duration safety and function beyond company-reported aggregate days? - How Neuralace and competing architectures (Neuralink, Synchron, Precision Neuroscience) will compare on chronic stability and regulatory paths. - Whether a dedicated `people/richard-normann.md` page would help separate inventor biography from platform history.